Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed locally advanced rectal cancer;~2. 18-70 years ；~3. Clinicalstage:T3,4a,N0,M0;T1-4a,N+,M0;~4. Tumor from anus \>5cm and ≤15cm;~5. ECOG=0-1;~6. Available organ function:ALT≤1.5xULN;AST≤1.5xULN;TBIL≤1.0xULN; NEUT≥2×109/L;PLT≥100×109/L;Hb≥90g/L;Creatinine≤1.0xULN;~7. Informed consent;~8. UGT1A1:UGT1A1\*1/UGT1A1\*1,UGT1A1\*1/UGT1A1\*28,UGT1A1\*1/UGT1A1\*6;~Exclusion Criteria:~1. Clinical stage T4b or unresectable disease;~2. History of pelvic radiotherapy;~3. History of chemotherapy within 5 years;~4. History of chronic diarrhea;~5. Tumor causes intestinal obstruction, intestinal perforation, and severe bleeding;~6. Hepatitis B surface antigen positive; Hepatitis C virus infection; Cirrhosis of the liver for any cause;~7. UGT1A1:UGT1A1\*28/UGT1A1\*28,UGT1A1\*6/UGT1A1\*6;~8. Other cancers in the past 5 years, except for cervical carcinoma in situ or non-melanoma skin cancer;~9. Myocardial infarction (in the last 6 months), severe instability angina, congestive heart failure; interstitial pneumonia,pulmonary fibrosis, uncontrolled diabetes, renal insufficiency;~10. Mental illness;Pregnant or lactating women;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOXIRI (Type: EXPERIMENTAL): oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).